| Identification | More | [Name]
N-Methyl-N-(naphthalen-1-ylmethyl)-1-(4-tert-butylphenyl)methanamine | [CAS]
101828-21-1 | [Synonyms]
BUTENAFINE
n-methyl-n-(naphthalen-1-ylmethyl)-1-(4-tert-butylphenyl)methanamine
n-(p-tert-butylbenzyl)-n-methyl-1-naphthalenemethylamine
N-methyl-N-(4-methylbenzyl)-N-(1-naphthylmethyl)amine
4-tert-Butylbenzylmethyl 1-naphtylmethylamine
N-(4-tert-Butylbenzyl)-N-methyl-1-naphthalenemethanamine | [Molecular Formula]
C23H27N | [MDL Number]
MFCD00865577 | [Molecular Weight]
317.47 | [MOL File]
101828-21-1.mol |
| Chemical Properties | Back Directory | [Melting point ]
200-202 °C | [Boiling point ]
426.1±14.0 °C(Predicted) | [density ]
1.032±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 63 mg/mL (198.44 mM);Ethanol: 63 mg/mL (198.44 mM) | [pka]
7.87±0.50(Predicted) | [Water Solubility ]
Water: Insoluble | [LogP]
6.770 (est) | [CAS DataBase Reference]
101828-21-1(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Uses]
Butenafine (Mentax) is a synthetic benzylamine antifungal agent, related structurally and pharmacologically to terbinafine. It is thought to act by inhibiting the enzyme squalene 2,3-epoxidase, resulting in decreased ergosterol and corresponding increase in squalene, with subsequent cell membrane permeability alteration and cell death. It is active against dermatophytes, yeast, and Sporothrix.
| [Definition]
ChEBI: Trimethylamine in which hydrogen atoms attached to different methyl groups are substituted by 1-naphthyl and 4-tert-butylphenyl groups. It is an inhibitor of squalene epoxidase, an enzyme responsible for the creation of sterols needed in funga
cell membranes, and is used as its hydrochloride salt for treatment of dermatological fungal infections. | [Brand name]
Lotrimin (Schering);
Mentax (Mylan Bertek). | [in vivo]
Butenafine (subcutaneous administration; 1-100 mg/kg) to mice has no effect on the central and autonomic nervous systems. Topical administration of 0.3-3.0% butenafine solutions to guinea pigs also has no effect on the somatic nervous system[1].In primary therapeutic studies on guinea pigs, Butenafine (1% topical application; 4-10 days; day 3 and 4 post-infection) exhibits a complete cure after 10 days in vivo-effect on dermatophytosis, T. mentagrophytes[1].Butenafine (0.125, 0.25, 0.5 and 1.0% topical application; q.d. or b.i.d. for 10 days; day 4 post-infection) exhibits a 100% cure after 0.5% or 1% application and has no difference in efficacy between 1% q.d. and b.i.d. in vivo-effect on dermatophytosis, T. mentagrophytes[1]. | [storage]
Store at -20°C |
|
|